MKNK1 and glioma: Furthermore, we propose that pharmacologically targeting WNT/β-catenin signaling by MNK1 inhibitors may have prophylactic or therapeutic potential specifically in (oligodendro)glioma patients harboring CDH1 variants affecting this pathway.